Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard C Becker

Showing results (371-380 of 436) with videos related to

Pageof 44
Sort By:
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.
Circulation|July 28, 2010
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary interventionMauricio G Cohen, Drew A Purdy, Joseph S Rossi, et al.
Circulation|May 22, 2002
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluationChristopher K Dyke, Richard C Becker, Neal S Kleiman, et al.
The New England Journal of Medicine|September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromesLars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Hypertension (Dallas, Tex. : 1979)|May 5, 2020
Subclinical Systolic and Diastolic Dysfunction Is Evident in Youth With Elevated Blood PressureAndrew H Tran, Joseph T Flynn, Richard C Becker, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 44

Showing results (371-380 of 436) with videos related to

Sort By:
Pageof 44
Annals of Internal Medicine|June 20, 2013
Clinical outcomes with rivaroxaban in patients transitioned from vitamin K antagonist therapy: a subgroup analysis of a randomized trialKenneth W Mahaffey, Daniel Wojdyla, Graeme J Hankey, et al.
Journal of the American Heart Association|March 5, 2015
Alternative calculations of individual patient time in therapeutic range while taking warfarin: results from the ROCKET AF trialDaniel E Singer, Anne S Hellkamp, Zhong Yuan, et al.
Circulation|July 28, 2010
First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary interventionMauricio G Cohen, Drew A Purdy, Joseph S Rossi, et al.
Circulation|May 22, 2002
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluationChristopher K Dyke, Richard C Becker, Neal S Kleiman, et al.
The New England Journal of Medicine|September 1, 2009
Ticagrelor versus clopidogrel in patients with acute coronary syndromesLars Wallentin, Richard C Becker, Andrzej Budaj, et al.
Circulation|February 21, 2014
Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF)Matthew W Sherwood, James D Douketis, Manesh R Patel, et al.
European Heart Journal. Quality of Care & Clinical Outcomes|September 17, 2018
Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AFSean T Chen, Anne S Hellkamp, Richard C Becker, et al.
Heart (British Cardiac Society)|February 19, 2016
Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxabanGünter Breithardt, Helmut Baumgartner, Scott D Berkowitz, et al.
Hypertension (Dallas, Tex. : 1979)|May 5, 2020
Subclinical Systolic and Diastolic Dysfunction Is Evident in Youth With Elevated Blood PressureAndrew H Tran, Joseph T Flynn, Richard C Becker, et al.
Journal of the American Heart Association|April 24, 2014
Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trialJonathan P Piccini, Anne S Hellkamp, Yuliya Lokhnygina, et al.
Pageof 44